The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 7, 2015, Pages 821-829

  Woods, Simone J ^a   Hannan, Katherine M ^a,b   Pearson, Richard B ^a,b,c   Hannan, Ross D ^a,b,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer therapy; Nucleolar stress; Nucleolus; P53; RNA polymerase I inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; CX 5461; DNA DIRECTED RNA POLYMERASE; ONCOPROTEIN; PROTEIN P53; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE; MYC PROTEIN; MYC PROTEIN, HUMAN; NAPHTHYRIDINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; TP53 PROTEIN, HUMAN;

BIOGENESIS; CANCER CELL; CANCER THERAPY; CELL STRESS; DNA DAMAGE; GENOTOXICITY; HUMAN; NEOPLASM; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; REVIEW; RIBOSOME; RNA TRANSLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; BENZOTHIAZOLES; CELL NUCLEOLUS; DNA DAMAGE; HUMANS; NAPHTHYRIDINES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RIBOSOMES; RNA POLYMERASE I; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930959601     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.10.007     Document Type: Review

References (123)

1. Rao B., Lain S., Thompson A.M. p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br. J. Cancer 2013, 109(12):2954-2958.
2. Bywater M.J., et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012, 22(1):51-65.
3. Hannan R.D., Drygin D., Pearson R.B. Targeting RNA polymerase I transcription and the nucleolus for cancer therapy. Expert Opin. Ther. Targets 2013, 17(8):873-878.
4. Burger K., et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem. 2010, 285(16):12416-12425.
5. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(6381):15-16.
6. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature 1991, 351(6326):453-456.
7. Harvey M., et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 1993, 5(3):225-229.
8. Donehower L.A., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356(6366):215-221.
9. Bieging K.T., Mello S.S., Attardi L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14(5):359-370.
10. Lane D.P., Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 2002, 8(4 Suppl.):S38-S42.
11. Brown C.J., et al. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9(12):862-873.
12. Momand J., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69(7):1237-1245.
13. Oliner J.D., et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362(6423):857-860.
14. Thut C.J., Goodrich J.A., Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997, 11(15):1974-1986.
15. Haupt Y., et al. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387(6630):296-299.
16. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387(6630):299-303.
17. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420(1):25-27.
18. Barak Y., et al. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993, 12(2):461-468.
19. Wu X., et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7(7A):1126-1132.
20. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene 2003, 22(56):9030-9040.
21. Nigro J.M., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342(6250):705-708.
22. Baker S.J., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244(4901):217-221.
23. Hoe K.K., Verma C.S., Lane D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014, 13(3):217-236.
24. Burger K., Eick D. Functional ribosome biogenesis is a prerequisite for p53 destabilization: impact of chemotherapy on nucleolar functions and RNA metabolism. Biol. Chem. 2013, 394(9):1133-1143.
25. Malhotra V., Perry M.C. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol. Ther. 2003, 2(4 Suppl. 1):S2-S4.
26. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68(21):8643-8653.
27. Lain S., Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur. J. Cancer 2003, 39(8):1053-1060.
28. Tyner S.D., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002, 415(6867):45-53.
29. Wallace W.H., et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ 2001, 323(7307):271-274.
30. Schwartz C.L. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 1999, 4(1):45-54.
31. Tovar C., et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013, 73(8):2587-2597.
32. Ray-Coquard I., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012, 13(11):1133-1140.
33. Hein N., et al. The nucleolus: an emerging target for cancer therapy. Trends Mol. Med. 2013, 19(11):643-654.
34. Quin J.E., et al. Targeting the nucleolus for cancer intervention. Biochim. Biophys. Acta 2014, 1842(6):802-816.
35. Bywater M.J., et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat. Rev. Cancer 2013, 13(5):299-314.
36. Palade G.E. A small particulate component of the cytoplasm. J. Biophys. Biochem. Cytol. 1955, 1(1):59-68.
37. Ruggero D., Pandolfi P.P. Does the ribosome translate cancer?. Nat. Rev. Cancer 2003, 3(3):179-192.
38. Pianese G., Teuscher R., Ziegler Ernst Beitrag zur Histologie und Aetiologie des Carcinoms: histologische und experimentelle Untersuchungen 1896.
39. Montanaro L., Trere D., Derenzini M. The emerging role of RNA polymerase I transcription machinery in human malignancy: a clinical perspective. Onco Targets Ther. 2013, 6:909-916.
40. Derenzini M., Montanaro L., Trere D. What the nucleolus says to a tumour pathologist. Histopathology 2009, 54(6):753-762.
41. Golomb L., Volarevic S., Oren M. p53 and ribosome biogenesis stress: the essentials. FEBS Lett. 2014, 588:2571-2579.
42. Drygin D., et al. Targeting the nucleolus for cancer-specific activation of p53. Drug Discov. Today 2014, 19(3):259-265.
43. Macias E., et al. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 2010, 18(3):231-243.
44. Drygin D., et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011, 71(4):1418-1430.
45. Moss T., et al. A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis. Cell. Mol. Life Sci. 2007, 64(1):29-49.
46. Grummt I. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. Genes Dev. 2003, 17(14):1691-1702.
47. Moss T. At the crossroads of growth control; making ribosomal RNA. Curr. Opin. Genet. Dev. 2004, 14(2):210-217.
48. Russell J., Zomerdijk J.C. RNA-polymerase-I-directed rDNA transcription, life and works. Trends Biochem. Sci. 2005, 30(2):87-96.
49. Hannan K.M., et al. Dysregulation of RNA polymerase I transcription during disease. Biochim. Biophys. Acta 2013, 1829(3-4):342-360.
50. Dai M.S., Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J. Cell. Biochem. 2008, 105(3):670-677.
51. Oskarsson T., Trumpp A. The Myc trilogy: lord of RNA polymerases. Nat. Cell Biol. 2005, 7(3):215-217.
52. Gomez-Roman N., et al. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem. Soc. Symp. 2006, 73:141-154.
53. Gomez-Roman N., et al. Direct activation of RNA polymerase III transcription by c-Myc. Nature 2003, 421(6920):290-294.
54. Poortinga G., Quinn L.M., Hannan R.D. Targeting RNA polymerase I to treat MYC-driven cancer. Oncogene 2014, 1-10.
55. Poortinga G., et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res. 2010, 39(8):3267-3281.
56. Ji H., et al. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One 2011, 6(10):e26057.
57. Poortinga G., et al. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J. 2004, 23(16):3325-3335.
58. Arabi A., et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat. Cell Biol. 2005, 7(3):303-310.
59. Grandori C., et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 2005, 7(3):311-318.
60. Hannan K.M., et al. Signaling to the ribosome in cancer-it is more than just mTORC1. IUBMB Life 2011, 63(2):79-85.
61. Zhao J., et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol. Cell 2003, 11(2):405-413.
62. Stefanovsky V.Y., et al. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol. Cell 2001, 8(5):1063-1073.
63. Chan J.C., et al. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci. Signal. 2011, 4(188):ra56.
64. Nguyen le X.T., Mitchell B.S. Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(51):20681-20686.
65. Devlin J.R., et al. AKT signalling is required for ribosomal RNA synthesis and progression of Emu-Myc B-cell lymphoma in vivo. FEBS J. 2013, 280(21):5307-5316.
66. Hannan K.M., et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 2003, 23(23):8862-8877.
67. Zhai W., Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell. Biol. 2000, 20(16):5930-5938.
68. Budde A., Grummt I. p53 represses ribosomal gene transcription. Oncogene 1999, 18(4):1119-1124.
69. Cavanaugh A.H., et al. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 1995, 374(6518):177-180.
70. Hannan K.M., et al. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 2000, 19(43):4988-4999.
71. Hannan K.M., et al. RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. Oncogene 2000, 19(31):3487-3497.
72. Chesnokov I., et al. p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner. Mol. Cell. Biol. 1996, 16(12):7084-7088.
73. Cairns C.A., White R.J. p53 is a general repressor of RNA polymerase III transcription. EMBO J. 1998, 17(11):3112-3123.
74. Zhang C., Comai L., Johnson D.L. PTEN represses RNA polymerase I transcription by disrupting the SL1 complex. Mol. Cell. Biol. 2005, 25(16):6899-6911.
75. Haddach M., et al. Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. ACS Med. Chem. Lett. 2012, 3(7):602-606.
76. Pestov D.G., Strezoska Z., Lau L.F. Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol. Cell. Biol. 2001, 21(13):4246-4255.
77. Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003, 22(22):6068-6077.
78. Yuan X., et al. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 2005, 19(1):77-87.
79. Holzel M., et al. Defects in 18S or 28S rRNA processing activate the p53 pathway. J. Biol. Chem. 2010, 285(9):6364-6370.
80. Bhat K.P., et al. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004, 23(12):2402-2412.
81. Dai M.S., et al. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 2004, 24(17):7654-7668.
82. Lohrum M.A., et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3(6):577-587.
83. Zhang Y., et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 2003, 23(23):8902-8912.
84. Marechal V., et al. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 1994, 14(11):7414-7420.
85. Jin A., et al. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 2004, 24(17):7669-7680.
86. Zhu Y., et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell 2009, 35(3):316-326.
87. Xiong X., et al. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 2011, 30(15):1798-1811.
88. Ofir-Rosenfeld Y., et al. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 2008, 32(2):180-189.
89. Kurki S., et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004, 5(5):465-475.
90. Saxena A., et al. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 2006, 25(55):7274-7288.
91. Weber J.D., et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1999, 1(1):20-26.
92. Kamijo T., et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(14):8292-8297.
93. Fumagalli S., et al. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev. 2012, 26(10):1028-1040.
94. Teng T., et al. Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. Mol. Cell. Biol. 2013, 33(23):4660-4671.
95. Fumagalli S., et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 2009, 11(4):501-508.
96. Bursac S., et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(50):20467-20472.
97. Golomb L., et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol. Cell 2012, 45(2):222-232.
98. Horn H.F., Vousden K.H. Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 2008, 27(44):5774-5784.
99. Donati G., et al. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep. 2013, 4(1):87-98.
100. Boisvert F.M., et al. A quantitative proteomics analysis of subcellular proteome localization and changes induced by DNA damage. Mol. Cell. Proteomics 2010, 9(3):457-470.
101. Boisvert F.M., Lamond A.I. p53-Dependent subcellular proteome localization following DNA damage. Proteomics 2010, 10(22):4087-4097.
102. Sasaki M., et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat. Med. 2011, 17(8):944-951.
103. Maehama T., et al. Nucleolar stress induces ubiquitination-independent proteasomal degradation of PICT1. J. Biol. Chem. 2014, 289:20802-20812.
104. Sundqvist A., et al. Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep. 2009, 10(10):1132-1139.
105. Kressler D., et al. Synchronizing nuclear import of ribosomal proteins with ribosome assembly. Science 2012, 338(6107):666-671.
106. Pan W., Issaq S., Zhang Y. The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression. PLoS One 2011, 6(6):e21625.
107. Abe T., et al. Inhibition of nucleolar function and morphological change by adriamycin associated with heat shock protein 70 accumulation. Jpn. J. Cancer Res. 1996, 87(9):945-951.
108. Choong M.L., et al. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 2009, 8(17):2810-2818.
109. Treiber D.K., et al. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl. Acad. Sci. U. S. A. 1994, 91(12):5672-5676.
110. Jordan P., Carmo-Fonseca M. Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res. 1998, 26(12):2831-2836.
111. Zhang H., Wang J.C., Liu L.F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(4):1060-1064.
112. Buckwalter C.A., et al. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res. 1996, 56(7):1674-1681.
113. Ghoshal K., Jacob S.T. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res. 1994, 54(3):632-636.
114. Pritchard D.M., et al. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(5):1795-1799.
115. Sun X.X., Dai M.S., Lu H. 5-Fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 2007, 282(11):8052-8059.
116. Andrews W.J., et al. Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. J. Biol. Chem. 2013, 288(7):4567-4582.
117. Snyder A.L., Kann H.E., Kohn K.W. Inhibition of the processing of ribosomal precursor RNA by intercalating agents. J. Mol. Biol. 1971, 58(2):555-565.
118. Colis L., et al. DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response. Oncotarget 2014, 5(12):4361-4369.
119. Peltonen K., et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 2014, 25(1):77-90.
120. Peltonen K., et al. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol. Cancer Ther. 2014, 13:2537-2546.
121. Nadine Hein D.D., O'Brien Sean, Cullinane Carleen, Matthews Geoff, Chesi Marta, Bergsagel Leif, Zuber Johannes, Lowe Scott, Johnstone Ricky, Pearson Rick, McArthur Grant, Hannan Ross Abstract B16: inhibition of RNA polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies. Cancer Res. 2013, 73.
122. Zhang Q., Shalaby N.A., Buszczak M. Changes in rRNA transcription influence proliferation and cell fate within a stem cell lineage. Science 2014, 343(6168):298-301.
123. Hayashi Y., et al. Downregulation of rRNA transcription triggers cell differentiation. PLoS One 2014, 9(5):e98586.